University of Florida College of Pharmacy

THERESA TOLLE NAMED 2023 NCPA WILLARD B. SIMMONS INDEPENDENT PHARMACIST OF THE YEAR

Retrieved on: 
Tuesday, October 17, 2023
Pharmacist, American Pharmacists Association, Medication therapy management, Upsher-Smith Laboratories, Automotive Executive of the Year Award, Health, NCPA, National Association, Trustee, University of Florida College of Pharmacy, University, MTM, Florida College, Lead, SAFIR, Patient, Pharmaceutical industry, Health care, Nursing, Pharmacy

MAPLE GROVE, Minn., Oct. 17, 2023 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) is pleased to announce that Theresa Tolle, BSPharm, FAPhA, owner of Bay Street Pharmacy in Sebastian, Florida, is the winner of the 2023 National Community Pharmacists Association (NCPA) Willard B. Simmons Independent Pharmacist of the Year award. Tolle was honored with the award on Monday, October 16 at NCPA's Annual Convention and Expo in Orlando, FL.

Key Points: 
  • MAPLE GROVE, Minn., Oct. 17, 2023 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) is pleased to announce that Theresa Tolle, BSPharm, FAPhA, owner of Bay Street Pharmacy in Sebastian, Florida, is the winner of the 2023 National Community Pharmacists Association (NCPA) Willard B. Simmons Independent Pharmacist of the Year award.
  • Tolle was honored with the award on Monday, October 16 at NCPA's Annual Convention and Expo in Orlando, FL.
  • The annual award is given to a pharmacist who exhibits exemplary professional leadership, service to community, and commitment to independent pharmacy.
  • The award is named in honor of Willard B. Simmons, a former executive secretary of NCPA (then known as the National Association of Retail Druggists) and a longtime trustee of the NCPA Foundation.

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer

Retrieved on: 
Wednesday, August 23, 2023
FCP, Drug development, Moses Austin, University, College, Pharming, Teaching, Betaxolol, Clementi, Worldwide, Agent handling, GCP, Research, Biomedical sciences, Zolpidem, Boston University, CDO, University of Texas Health Science Center at San Antonio, EMA, University of Florida College of Pharmacy, CGMP, Sanofi, Patient, DBA, Fellow, IND, Faculty, Growth, FDA, Pharmacology, NIH, Pharmaceutical industry, Nursing, Tiziana, Medicine

NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer.

Key Points: 
  • NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer.
  • His deep understanding of drug development and his strategic insights will be invaluable as Tiziana continues to advance its pipeline.
  • Commenting on his new role, William A. Clementi said, "I am excited to join Tiziana Life Sciences and contribute to the advancement of its innovative therapeutic candidates.
  • Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences, expressed his enthusiasm about the appointment, stating, "We are delighted to welcome William to Tiziana as our Chief Development Officer.

Sparian Biosciences Awarded $19 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development

Retrieved on: 
Tuesday, August 8, 2023
University of Florida College of Pharmacy, Stud, Substance abuse, SR, Florida College, University, Therapy, Methamphetamine, Public, DOR, Opioid use disorder, The Help, OUD, Brain, Dopamine, Harvard Medical School, CNS, Government, Pain, Entrepreneurship, Cocaine, Central nervous system disease, DAT, National Institute on Drug Abuse, NIDA, MOR, HEAL, IND, Drug, Pharmaceutical industry, Pharmacy

SBS-518 is a first-in-class dual sigma receptor (SR) antagonist/dopamine transporter (DAT) inhibitor in development for the treatment of stimulant use disorder (StUD).

Key Points: 
  • SBS-518 is a first-in-class dual sigma receptor (SR) antagonist/dopamine transporter (DAT) inhibitor in development for the treatment of stimulant use disorder (StUD).
  • StUD is a subset of substance use disorders that includes cocaine and methamphetamine use disorders.
  • The grant was awarded by NIH/NIDA under the Help End Addiction Long-Term (HEAL) initiative.
  • Since its founding, Sparian has been awarded a total of $41 million in government grants to support three programs.

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

Retrieved on: 
Thursday, July 27, 2023
DED, FCP, Drug development, Moses Austin, University, Therapy, College, Pharming, Teaching, Biotechnology, Betaxolol, Clementi, Worldwide, NDA, GCP, Agent handling, Lead, Research, Biomedical sciences, Zolpidem, Boston University, University of Texas Health Science Center at San Antonio, EMA, Telecanthus, University of Florida College of Pharmacy, CGMP, Sanofi, DBA (airline), Fellow, IND, Faculty, Growth, FDA, Pharmacology, NIH, Pharmaceutical industry, Nursing, Medicine

Mr. Clementi's extensive experience in the pharmaceutical industry and his achievements make him a valuable addition to the OKYO Pharma team.

Key Points: 
  • Mr. Clementi's extensive experience in the pharmaceutical industry and his achievements make him a valuable addition to the OKYO Pharma team.
  • In 1991 Dr. Clementi established a regulatory consulting company, Clementi & Associates, Ltd. (dba as Clementi Ltd).
  • "We are delighted to welcome William Clementi to OKYO Pharma as our new Chief Operating Officer.
  • Dr. Clementi's appointment comes at a crucial time for OKYO Pharma, with significant milestones on the horizon.

Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants

Retrieved on: 
Wednesday, June 21, 2023
Partnership, University, College, Therapy, University of Tennessee Health Science Center, U.S. Department of Defense Strategy for Operating in Cyberspace, Pharmacy, The College of Medicine, SARS-CoV-2, UTHSC, United States Department of Defense, Cancer, National Cancer Institute, Research, Government, University of Florida College of Pharmacy, NCI, Distinguishing, Breast cancer, Pharmaceutical industry, Pathology, Verus Pharmaceuticals

MIAMI, FL, June 21, 2023 (GLOBE NEWSWIRE) -- The University of Tennessee Health Science Center (UTHSC), oncology drug discovery research partner to Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, has secured two additional grants to develop oncology therapeutics for indications of high unmet need. UTHSC was awarded $924,000 from the U.S. Department of Defense (DoD) and $3,074,470 from the National Cancer Institute’s Research Project Grant (NCI R01). These two new grants awarded to UTHSC bring the university’s aggregate oncology funding related to this project to over $10 million.

Key Points: 
  • UTHSC was awarded $924,000 from the U.S. Department of Defense (DoD) and $3,074,470 from the National Cancer Institute’s Research Project Grant (NCI R01).
  • These two new grants awarded to UTHSC bring the university’s aggregate oncology funding related to this project to over $10 million.
  • Validation of this research approach is reflected in peer-reviewed support from the U.S. government in the form of two awarded grants.
  • We are committed to collaborating with our clinical partner, Veru, who may ultimately pursue for late-stage clinical drug development.”

University of Connecticut Takes First Place in AMCP Foundation Case Study Competition for Future Pharmacists

Retrieved on: 
Friday, April 7, 2023
University of Florida College of Pharmacy, CT, CAE, University, University of Minnesota College of Pharmacy, Florida College, Doctor of Pharmacy, AMCP, Health equity, Roche, Atopic dermatitis, MBA, Executive sponsor, Genentech, P&T, Competition, School, Pharmacist, Patient, Tralokinumab, Disease, Pharmaceutical industry, Pharmacy

First Place: University of Connecticut School of Pharmacy, Storrs, CT

Key Points: 
  • First Place: University of Connecticut School of Pharmacy, Storrs, CT
    Second Place: University of Washington School of Pharmacy, Seattle, WA
    Third Place: University of Minnesota College of Pharmacy, Minneapolis, MN
    Additionally, University of Southern California School of Pharmacy, and University of Florida College of Pharmacy competed in the live national finals.
  • Student pharmacists reviewed the drug dossier in the AMCP Format for Formulary Submissions and presented to a mock P&T Committee.
  • "This competition is the marquee event for student pharmacists who are interested in managed care," said AMCP Foundation executive director Paula J. Eichenbrenner, MBA, CAE.
  • AMCP Foundation thanks LEO Pharma Inc., for use of the Adbry dossier for this competition and FormularyDecisions for hosting AMCP eDossiers.

Drug Safety Institute & NSU College of Pharmacy Present Alexios Skarlatos, Chair of the EMA's Name Review Group (NRG), with the 15th Annual National Patient Safety Award

Retrieved on: 
Monday, November 21, 2022
Head, EMA, European Medicines Agency, Translation Centre for the Bodies of the European Union, Quality assurance, Safety, Minister (government), QRD, DSI, University of Florida College of Pharmacy, Brand Institute, College, Stormwatch: Post Human Division, European Institute, City Environmental Quality Review, Judicial Studies Center, NSU, NRG, Medical device, Pharmaceutical industry, Pharmacy, EU

MIAMI, Nov. 21, 2022 /PRNewswire/ -- Brand Institute is delighted to announce the recipient of the 15th annual Stephanie F. Aleong, J.D., National Patient Safety Award.

Key Points: 
  • MIAMI, Nov. 21, 2022 /PRNewswire/ -- Brand Institute is delighted to announce the recipient of the 15th annual Stephanie F. Aleong, J.D., National Patient Safety Award.
  • The award, a co-sponsorship between Brand Institute's subsidiary, Drug Safety Institute (DSI), and NSU College of Pharmacy, was presented to Alexios Skarlatos on Saturday, November 5th, 2022, for his achievements and thought leadership in patient safety in labeling, packaging, and information review for centrally authorized pharmaceutical products in Europe.
  • The award was presented during NSU College of Pharmacy's NSU Fall Classic continuing education conference that took place on November 5th and 6th.
  • The original award is displayed in the College of Pharmacy with profiles on all recipients.

TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology at Respiratory Drug Delivery Meeting (RDD)

Retrieved on: 
Monday, May 2, 2022
Drug development, Pulmonary fibrosis, Inhalation, Safety, Exhibition, Interface, Powder, Poster, Annual report, Artificial intelligence, Skin, Young Scientist and Technology Exhibition, University of Florida College of Pharmacy, Antibody, Solubility, Technology, CEO, Risk, Fight Against Coercive Tactics Network, NASDAQ, Water, BioRxiv, Company, Voriconazole, College, Lung, FDA, Government, Research, Freezing, Podium, University of Texas at Austin, RDD, Degenerative disease, Vaccine, Cros, Protein, COVID-19, Escherichia coli, Absorption, GLOBE, University, TFF, Nose, Medical device, Pharmaceutical industry, Lactoferrin

FORT WORTH, Texas, May 02, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced substantial new data to be presented on its technology platform at the Respiratory Drug Delivery (RDD) Meeting, which is taking place between May 1-5, 2022 in Orlando, Florida.

Key Points: 
  • (Bill) Williams III, Ph.D., co-inventor of Thin Film Freezing technology and special advisor to TFF Pharmaceuticals, will deliver a platform presentation with data on stabilizing and delivering antivirals, antibodies and vaccines using Thin Film Freezing technology in the fight against COVID-19 and other serious viral infections.
  • Additionally, Dr. Williams and his colleagues will present five posters highlighting the broad applicability of Thin Film Freezing to improve drug development of biologics and small molecules for respiratory diseases, including pulmonary fibrosis and COVID-19.
  • The findings from Dr. Williams lab also highlight how Thin Film Freezing can be used to facilitate delivery of other treatment modalities, such as gene therapy.
  • "We are excited to share these data showcasing the incredible versatility of the Thin Film Freezing platform at the RDD conference," said Glenn Mattes, CEO of TFF Pharmaceuticals.

Study Finds Cannabinoids Block COVID-19: Prof. Richard van Breemen from OSU to Keynote 7th Semi-Annual Cannabis Science Conference West in Long Beach, California

Retrieved on: 
Monday, February 7, 2022
Policy, GLOBE, Industry, Alchemy, Johns Hopkins, Science, Conference, Athlete, Champaign County, Illinois, Infection, Herbal cigarette, Research, COVID-19, Natural product, North Carolina State University, University of Florida College of Pharmacy, Linus Pauling Institute, Golden, Entertainment, Johns Hopkins University, Safety, University, Severe acute respiratory syndrome coronavirus 2, CBDA, CSC, Golden State, Founder, CEO, Cannabis, College, Journal, Oregon State University, Disease, Long Beach Convention and Entertainment Center, Journal of Natural Products, Oberlin College, CBGA, Cell, LLC, Drug, Vaccine, Pharmaceutical industry, Pharmacy, Pharmacology, Chemistry

LONG BEACH, CA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Cannabis Science Conference, the world's largest, fastest growing and most technical scientific and medical cannabis event, announced today that world-renowned researcher, Prof. Richard van Breemen, Ph.D., will present a keynote address at its first-ever Golden State edition of Cannabis Science Conference in Long Beach, California, at the Long Beach Convention and Entertainment Center that has been rescheduled to May 18-20.

Key Points: 
  • Your safety and well-being are our number one priority as we work together to continue advancing cannabis science.
  • Cannabis Science Conference is the world's largest & fastest growing cannabis science event.
  • Our conferences have a specialized focus on analytical science, medical cannabis, cultivation science, hemp/CBD science & psychedelic science.
  • Join us in Long Beach, CA (May 18-20, 2022) for an exciting conference with keynotes, presentations, round table discussions and exhibits.

Dialectic Therapeutics Receives $14.4 Million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas

Retrieved on: 
Friday, August 20, 2021
Company, University of Texas Health Science Center at San Antonio, SEED, University, Cancer, University of Florida College of Pharmacy, Research, Therapy, Cell, Chemistry, Florida College, Patient, Texaco, Organization, Long School, Financial toxicity, UT Health San Antonio Cancer Center, University of Florida Health, New product development, Relational dialectics, Pharmaceutical industry

DALLAS, Aug. 20, 2021 /PRNewswire/ -- Dialectic Therapeutics, Inc. (Dialectic), a Texas-based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer, today announced it has received a $14.4 million Texas Company (TXCO) Product Development Research Award from the Cancer Prevention & Research Institute of Texas (CPRIT).

Key Points: 
  • DALLAS, Aug. 20, 2021 /PRNewswire/ -- Dialectic Therapeutics, Inc. (Dialectic), a Texas-based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer, today announced it has received a $14.4 million Texas Company (TXCO) Product Development Research Award from the Cancer Prevention & Research Institute of Texas (CPRIT).
  • This grant adds to the initial $3 million Seed Award that Dialectic received from CPRIT in 2020, which was instrumental in supporting preclinical studies.
  • Dialectic has also been supported to date through a Seed Award for Product Development Research from CPRIT.
  • Dialecticis a registered trademark of Dialectic Therapeutics, Inc.
    To date, CPRIT has awarded $2.9 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs.